"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 3 | 3 |
| 2000 | 4 | 2 | 6 |
| 2001 | 2 | 5 | 7 |
| 2002 | 5 | 6 | 11 |
| 2003 | 4 | 5 | 9 |
| 2004 | 4 | 3 | 7 |
| 2005 | 6 | 2 | 8 |
| 2006 | 2 | 2 | 4 |
| 2007 | 3 | 3 | 6 |
| 2008 | 3 | 6 | 9 |
| 2009 | 12 | 7 | 19 |
| 2010 | 8 | 7 | 15 |
| 2011 | 8 | 7 | 15 |
| 2012 | 3 | 10 | 13 |
| 2013 | 10 | 7 | 17 |
| 2014 | 17 | 11 | 28 |
| 2015 | 7 | 5 | 12 |
| 2016 | 12 | 7 | 19 |
| 2017 | 18 | 13 | 31 |
| 2018 | 19 | 14 | 33 |
| 2019 | 14 | 14 | 28 |
| 2020 | 24 | 15 | 39 |
| 2021 | 15 | 21 | 36 |
| 2022 | 2 | 32 | 34 |
| 2023 | 3 | 19 | 22 |
| 2024 | 12 | 18 | 30 |
| 2025 | 19 | 7 | 26 |
| 2026 | 4 | 8 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Lymph nodes now optional. Science. 2026 Jul 16; 393(6808):242-243.
-
Evaluating mesothelin as an immunotherapeutic target for endogenous T cells. Front Immunol. 2026; 17:1853409.
-
Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity. Med. 2026 Jul 10; 7(7):101149.
-
Immune checkpoint inhibitor resistance in non-small cell lung cancer: An updated view through the cancer-immunity cycle. Crit Rev Oncol Hematol. 2026 Sep; 225:105382.
-
Biodegradable nanofibrous drug-eluting seed for sustained intratumoral immunotherapy. J Control Release. 2026 07 10; 395:115004.
-
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases. J Immunother Cancer. 2026 May 04; 14(5).
-
Oncolytic viruses and cytokine-based gene therapies reprogram the tumor microenvironment. Nat Cancer. 2026 May; 7(5):723-739.
-
Safety and effectiveness of immune checkpoint inhibitors in older adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease - A SEER-Medicare study. J Geriatr Oncol. 2026 May; 17(4):102971.
-
Immunotherapy approaches for the treatment of relapsed or progressive medulloblastoma. J Neurooncol. 2026 Mar 11; 177(1).
-
Established and Emerging Therapies for High-Risk Neuroblastoma. Paediatr Drugs. 2026 Mar; 28(2):159-175.